AIM
AIM ImmunoTech
31 hedge funds and large institutions have $2.05M invested in AIM ImmunoTech in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less first-time investments, than exits
New positions opened: | Existing positions closed:
Holders
31
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$16.5K | |
| 2 | +$10.4K | |
| 3 | +$1.76K | |
| 4 |
TSS
Two Sigma Securities
New York
|
+$1.14K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$881 |
Top Sellers
| 1 | -$159K | |
| 2 | -$49.5K | |
| 3 | -$21.9K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$20.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$15.2K |